Research, reports, policy briefs, and formal comments from Americans for Safe and Effective Medicines.
Selected reading
National Surveys
84% of consumers say FDA approval matters. Half of current GLP-1 users mistakenly believe compounded versions have it — and physicians are seeing the same confusion in their exam rooms. A one-page summary of ASEM’s consumer and physician survey findings.
DownloadReport
ASEM’s report on how illegal mass compounding is undermining patient safety — and what must happen next.
View ReportPolicy Brief
Key findings and recommendations from ASEM’s report on illegal mass compounding — unsafe practices, illicit supply chains, and the misleading marketing keeping patients in the dark.
View Policy BriefComment Letter
ASEM’s comment to the FDA urging the agency to finalize its proposal to exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List.
View Comment Letter